156 related articles for article (PubMed ID: 32702989)
1. Distinct Metabolic Signatures of Hormone-Sensitive and Castration-Resistant Prostate Cancer Revealed by a
Zheng H; Zhu Y; Shao X; Cai A; Dong B; Xue W; Gao H
J Proteome Res; 2020 Sep; 19(9):3741-3749. PubMed ID: 32702989
[TBL] [Abstract][Full Text] [Related]
2. NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer.
Zheng H; Dong B; Ning J; Shao X; Zhao L; Jiang Q; Ji H; Cai A; Xue W; Gao H
Clin Chim Acta; 2020 Feb; 501():241-251. PubMed ID: 31758937
[TBL] [Abstract][Full Text] [Related]
3. Identification of characteristic metabolic panels for different stages of prostate cancer by
Zhang X; Xia B; Zheng H; Ning J; Zhu Y; Shao X; Liu B; Dong B; Gao H
J Transl Med; 2022 Jun; 20(1):275. PubMed ID: 35715864
[TBL] [Abstract][Full Text] [Related]
4. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.
Liu P; Wang W; Wang F; Fan J; Guo J; Wu T; Lu D; Zhou Q; Liu Z; Wang Y; Shang Z; Chan FL; Yang W; Li X; Zhao SC; Zheng Q; Wang F; Wu D
J Transl Med; 2023 Jan; 21(1):40. PubMed ID: 36681849
[TBL] [Abstract][Full Text] [Related]
5. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients.
Komiya A; Yasuda K; Watanabe A; Fujiuchi Y; Tsuzuki T; Fuse H
Mol Clin Oncol; 2013 Mar; 1(2):257-262. PubMed ID: 24649157
[TBL] [Abstract][Full Text] [Related]
7. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
8. Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z; Yan X; Tang P; Tang T; Wang Y; Peng S; Wang S; Lan W; Wang L; Zhang Y; Zhang J; Li K; Shu Z; Xu J; Qin J; Zhang D; Jiang J; Liu Q
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):180-187. PubMed ID: 36401126
[TBL] [Abstract][Full Text] [Related]
9. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer.
Wu F; Ning H; Sun Y; Wu H; Lyu J
Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
[TBL] [Abstract][Full Text] [Related]
11. NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Kumar D; Gupta A; Mandhani A; Sankhwar SN
Prostate; 2016 Sep; 76(12):1106-19. PubMed ID: 27197810
[TBL] [Abstract][Full Text] [Related]
12. NMR-based metabolomics studies of human prostate cancer tissue.
Lima AR; Pinto J; Bastos ML; Carvalho M; Guedes de Pinho P
Metabolomics; 2018 Jun; 14(7):88. PubMed ID: 30830350
[TBL] [Abstract][Full Text] [Related]
13. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.
Huang J; Liu D; Li J; Xu J; Dong S; Zhang H
Ann Med; 2023; 55(2):2260387. PubMed ID: 37729607
[TBL] [Abstract][Full Text] [Related]
14. Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer.
Matsumoto T; Hatakeyama S; Yoneyama T; Tobisawa Y; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Ito H; Nishimura SI; Ohyama C
Sci Rep; 2019 Nov; 9(1):16761. PubMed ID: 31727974
[TBL] [Abstract][Full Text] [Related]
15. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
16. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
[TBL] [Abstract][Full Text] [Related]
18.
Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
[TBL] [Abstract][Full Text] [Related]
19. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
[TBL] [Abstract][Full Text] [Related]
20. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]